Clinical Trials · NCT04478266
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Sanofi
- Enrollment
- 1,068
- Start date
- Oct 2020
- Locations
- 249 sites, 30 countries
- Primary endpoint
- Progression-free Survival (PFS)